United States Patent 9,522,117: Scope, Claim Architecture, and US Landscape
US Patent 9,522,117 is directed to oral tablet formulations and manufacturing and use methods built around micronized bromocriptine mesylate (and related bromocriptine forms) combined with excipients, with scope anchored to three technical pillars: (i) tight particle-size specifications (Dv90 and, in some dependent claims, Dv99 and “span”), (ii) dissolution performance measured in USP Apparatus Type 2 at 50 rpm in 0.1 N HCl at 37 °C with defined release windows, and (iii) dose strength tied to at least 0.8 mg bromocriptine per tablet (including a recurring “about 0.8 mg” embodiment). Claims also extend into methods of manufacture (including processing/micronization, uniform blending, and compression) and into methods of treatment for improving glycemic control in type 2 diabetes.
What is the core claim scope in US 9,522,117?
The independent claim cluster is claim 1 (tablet) and claim 9 (manufacture method). Claim 19 and claim 20 then tether use/treatment to the composition and manufacture embodiments. Claims 21 to 61 broaden into additional dosage-form and PK-oriented formulations by adding parameters such as “span” and specific Tmax windows under fasting vs high-fat fed conditions.
Independent Claim 1 (tablet) sets the formulation boundary
Claim 1 requires all of the following:
- Dosage form: “A tablet comprising”
- Active: micronized bromocriptine mesylate
- Dose: particle amount “provides a dose of at least about 0.8 mg of bromocriptine per tablet”
- Particle size: micronized bromocriptine mesylate has Dv90 < about 10 µm
- Dissolution test: USP Apparatus Type 2 Paddle, 50 rpm, 500 mL of 0.1 N HCl, 37 °C
- Dissolution criterion at 30 min: ≥ about 90% released at about 30 minutes
This combination makes claim 1 less about “bromocriptine in tablets” and more about a narrow parameter space: micronized mesylate with Dv90 below 10 µm plus rapid gastric acid dissolution reaching ≥90% at 30 minutes.
Independent Claim 9 (manufacture method) mirrors the tablet spec
Claim 9 requires:
- Processing bromocriptine mesylate to reduce average particle size to Dv90 < about 20 µm
- Blending with excipients so bromocriptine is “substantially evenly distributed”
- Compressing into tablets
- Tablet includes:
- dose ≥ about 0.8 mg bromocriptine
- USP2 dissolution: ≥ about 90% released at about 30 minutes (same apparatus/media as claim 1)
Notably, claim 9 sets a higher Dv90 threshold after processing (<20 µm) than claim 1 for the finished product (<10 µm). That leaves room for the finished tablet to meet a tighter distribution even if processing targets a broader threshold.
Other independent-like anchors
While the independent claims are 1 and 9 (and treatment anchors 19/20), the claim set includes additional substantial independent-formulation platforms in claims 21 and 22 as they introduce pharmacokinetic (Tmax) and additional particle-size descriptors (“span” in claim 21; dissolution at 30 min in claim 22).
How do the dependent claims expand or narrow protection?
The dependent claims create a matrix of particle-size targets, dissolution performance profiles, and PK-related boundaries. The practical effect is to capture multiple routes to the same technical outcome and to ladder narrower formulations under broader ones.
Particle-size ladder
- Dv90 thresholds
- Claim 1: Dv90 < 10 µm
- Claim 3: Dv90 < 5 µm (tighter)
- Claim 28/29: dosage-form Dv90 < 20 µm and < 10 µm
- Dv99 thresholds
- Claim 4: Dv99 < 15 µm
- Claim 41/52: dosage-form Dv99 < 15 µm (with repeated use)
- Fine fraction constraints
- Claim 5: volume-based distribution: not more than ~20% < 1 µm
- Claim 31 and claim 43/51: repeated in dosage-form variants (sometimes paired with span and other dissolution/PK criteria)
- Span constraint (PSD shape metric)
- Claim 21 and claim 23: span about 2 or lower
- Claim 51/53/57: span about 2 or lower incorporated into micronized mesylate or bromocriptine embodiments
Dissolution window options
The claims do not only fix “≥90% at 30 minutes.” They also define earlier-time behavior and an alternative threshold at 30 minutes.
- ≥90% at 30 min
- Claim 1
- Claim 54 (dosage form)
- Claim 59 (dosage form)
- Claim 57 (80% at 30 min, but also tracks earlier-time limits)
- ≥95% at 30 min
- ≥90% at 20 min
- Early release ceiling profile (countermeasure to “too fast”)
- Claim 8: at 7 min ≤50% and 10 min ≤75%, while still reaching ≥90% at 30 min
- Claim 16: method mirrors claim 8
- Claim 34 and claim 46: dosage form versions mirror the same ceiling scheme
This structure indicates the patentee targeted not only overall dissolution extent but also a kinetic signature consistent with “rapid but not explosively early” release.
Dose strength is repeatedly fixed
- “at least about 0.8 mg per tablet” appears across claim 1 and claim 9 as the floor.
- “about 0.8 mg” shows up in claim 2 and claim 10 for tighter scope.
- Dosage-form claims 26/27 and 42/47/50/51/57 embed dose and dissolution and particle-size boundaries.
Pharmacokinetic (PK) scope in claims 21 and 35
Claim 21 (dosage form) adds:
- absorption of a “substantial amount” through gastric and/or intestinal mucosa (functional language)
- span about 2 or lower
- Tmax windows:
- fasting Tmax 30 to 60 minutes, or
- high-fat fed Tmax 90 to 120 minutes
Claim 35 adds the same PK boundary to a dosage-form context.
This PK language shifts the legal scope from pure in vitro performance to an in vivo performance wrapper. For infringement arguments, PK claims typically require matching the formulation to the claimed Tmax conditions under the specified feeding status.
Tightest integrated formulation claim
Claim 51 combines multiple “most constrained” elements in one dependent chain:
- micronized bromocriptine mesylate
- Dv90 < 10 µm
- volume-based PSD with span about 2 or lower (by claim 53, depending which claim’s scope is used)
- fine fraction: not more than ~20% < 1 µm
- dissolution kinetics ceiling at early time:
- ≤50% at 7 min
- ≤75% at 10 min
- and release extent:
- ≥80% at 30 min (per claim 51)
This creates a high-specificity “corner” that is likely difficult to design around without changing PSD or excipient system substantially.
What is the legal claim architecture for treatment and method-of-use?
Type 2 diabetes treatment
- Claim 19: method of treatment for improving glycemic control in a type 2 diabetes patient by administering the tablet of claim 1.
- Claim 20: method of treatment by preparing tablets via claim 9 method and providing the tablet for administration.
- Claims 36, 48, 55, 60: additional method-of-treatment dependents tied to dosage-form claims 23, 38, 51, 57 respectively.
- Morning dosing constraint:
- Claim 37, claim 49, claim 56, claim 61: “administered in the morning within about two hours after waking.”
This dosing-time language narrows treatment methods. It also offers a practical evidentiary path: timing adherence and prescribed regimen can be used to match the claimed method if the formulation matches the dosage-form parameter set.
How does claim scope separate “bromocriptine” vs “bromocriptine mesylate”?
The patent uses “bromocriptine” broadly in certain dosage-form claims but repeatedly locks the active to mesylate where particle-size and dissolution rules are tested.
Key splits:
- Mesylate-centric: claim 1, claim 9, and many dosage-form constraints for micronized mesylate.
- Bromocriptine salt/general bromocriptine: claims 23, 24, 25, 38-40, 44, 45, 50.
- PK-related claims: claim 21 and claim 35 cite “bromocriptine” without always spelling out mesylate in the same independent claim block, but dependent claim 40/42/47 and adjacent constraints reintroduce mesylate and particle-size details.
From a landscape and design-around standpoint, the key is whether a competitor uses the same salt form plus matching PSD and dissolution/PK signatures.
What is the likely patent landscape around US 9,522,117 in the US bromocriptine reformulation space?
US 9,522,117 sits in a common reformulation corridor: extending patent life or protecting new composition and process claims built on micronization, PSD control, and dissolution/PK improvements for oral absorption of bromocriptine.
Where this patent is strongest
The patent’s strongest defensibility is in claims tied to specific measurable specifications:
- Dv90 < 10 µm for micronized bromocriptine mesylate (claim 1)
- Dissolution profile in 0.1 N HCl USP2 at 50 rpm with numeric release windows (claims 1, 6-8, 16, 33-34, 45-46, 51)
- PSD distribution shape metrics like span (claims 21, 23, 53, 57)
- Tmax windows under fasting vs high-fat fed conditions (claim 21, claim 35)
Those elements are harder to “implicitly satisfy” unless a generic applicant chooses a formulation that produces the same PSD and performance.
Where this patent is easiest to design around
The design-around levers are the ones the claims explicitly lock:
- increase Dv90 above the thresholds (10 µm or 5 µm depending on claim)
- shift dissolution timing so it breaches the early-time ceilings at 7 and 10 minutes (claims 8/16/34/46/51)
- modify PSD fines fraction (the “not more than 20% < 1 µm” requirement)
- change span above about 2
- adjust formulation to move Tmax outside 30-60 (fasting) or 90-120 (high-fat fed)
A competitor can also target different salt forms, though the claims include “salt of bromocriptine” as options in certain dependent paths.
Scope-by-claim map (what each claim protects in practice)
| Claim(s) |
What is protected |
Key technical limits |
| 1 |
Tablet composition (bromocriptine mesylate, micronized) |
Dose ≥0.8 mg; Dv90 <10 µm; USP2 50 rpm 0.1 N HCl 500 mL 37 °C; ≥90% release at ~30 min |
| 2 |
Narrowed dose |
dose about 0.8 mg |
| 3-4 |
PSD tightening |
Dv90 <5 µm; Dv99 <15 µm |
| 5 |
PSD fines control |
≤20% by volume <1 µm |
| 6 |
Dissolution tightening |
≥95% at ~30 min |
| 7 |
Faster dissolution metric |
≥90% at ~20 min |
| 8 |
Dissolution kinetic signature with early ceilings |
≤50% at 7 min and ≤75% at 10 min; still ≥90% at 30 min |
| 9-17 |
Method of manufacture |
Process to Dv90 <20 µm; blend uniform; compress; tablet meets dose and dissolution ≥90% at 30 min; plus manufacturing logistics in dependent claims |
| 19-20 |
Treatment method |
Improves glycemic control by administering the claim 1 tablet or claim 9-made tablets |
| 21 |
Dosage form with PK envelope |
span ≤2; fasting Tmax 30-60 min or high-fat Tmax 90-120 min |
| 22-27, 28-32 |
Dosage-form composition variants |
dissolution ≥80% at 30 min; PSD Dv90/Dv99; salts and micronization options; dose floor |
| 33-34 |
Dosage-form dissolution profiles with early ceilings |
≥90% at 30 min and early ceiling rules |
| 35 |
Dosage-form PK envelope |
Tmax windows (fasting/high-fat) |
| 36-37, 48-49, 55-56, 60-61 |
Treatment methods with timing |
morning within about two hours after waking |
| 38-47 |
Dosage form variants |
Dv90 <10; dissolution ≥80%/≥90% variants; early ceilings; Tmax windows; salt and mesylate options |
| 50-54 |
Micronized mesylate dosage variants |
Dv99 <15; fines/sizing and ≥80% at 30 min |
| 51-53 |
Highest-integrity dosage formulation |
micronized mesylate; Dv90 <10; fines and early ceiling plus ≥80% at 30 min |
| 57-61 |
Integrated dosage formulation variants |
Dv90 <10; span ≤2; dissolution ≥80% at 30 min; plus ≥90% and treatment timing dependents |
Practical infringement focus: which claim elements are most likely to be tested in a US regulatory or litigation setting?
In US generic and reformulation disputes, the most frequently litigated technical linkages tend to be those that are measurable in vitro and directly tied to the product:
- Particle-size distributions (Dv90, Dv99, span, fines fraction)
- Dissolution in defined conditions (USP2 paddle, 50 rpm, 0.1 N HCl, 500 mL, 37 °C, numeric timepoints)
- Dose strength (0.8 mg floor and “about 0.8 mg” embodiment)
- PK/Tmax claims (for those asserted, matching typically requires fed/fasted study conditions)
Treatment claims usually require matching the prescribed regimen and patient population (type 2 diabetes) and verifying that the administered product is the claimed dosage form.
Key takeaways
- US 9,522,117 protects bromocriptine mesylate tablet formulations built on micronized PSD control (chiefly Dv90 thresholds), defined USP2 acid dissolution release kinetics, and a dose floor of ≥0.8 mg.
- The claim set is parameter-dense: it includes tight PSD targets (Dv90 <10 µm; Dv99 <15 µm; fines fraction ≤20% <1 µm; span ≤2), dissolution extent targets (≥80%, ≥90%, ≥95% at 30 min depending on claim), and kinetic “shape” constraints (early ceilings at 7 and 10 min).
- The patent adds an in vivo wrapper via Tmax windows (fasting 30-60 min; high-fat 90-120 min) and narrows treatment methods through timing (morning within about two hours after waking).
- The most actionable design-around variables are: PSD thresholds, fine fraction, dissolution early-time behavior, and PK/Tmax position under fasting vs high-fat conditions.
FAQs
1) What is the single most important constraint in claim 1?
Dv90 < about 10 µm for micronized bromocriptine mesylate, combined with tablet dissolution reaching at least about 90% released at about 30 minutes in USP2 paddle (0.1 N HCl, 37 °C).
2) Does the patent require micronization only, or can PSD be met by other processing?
The claims repeatedly specify micronized form and particle-size distributions defined by Dv90/Dv99/span metrics. In the manufacture claim (claim 9), “processing” includes micronizing as an express dependent option (claim 13).
3) How do the “early-time ceilings” change the scope?
They limit formulations that release too quickly early. For example, claims 8/16/34/46 constrain release to “not more than about 50% at 7 min” and “not more than about 75% at 10 min” while still meeting the later 30-minute release requirement.
4) What is the role of the Tmax limitation in the landscape?
Claims 21 and 35 attach a PK envelope to the dosage form (fasting Tmax 30-60 minutes or high-fat Tmax 90-120 minutes). If asserted, an accused product must match those fed/fasted conditions to fall within that claim territory.
5) Which claim elements are most likely to be decisive in an infringement analysis?
Measured particle-size and dissolution performance in the specified USP2 acid conditions, plus meeting the numeric dose and meeting (where asserted) PK/Tmax and treatment regimen timing.
References
[1] United States Patent No. 9,522,117. Claims text provided in the prompt.
